Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/26/2025

STD Screening Recommendations

Core Components of STD Panel

  • The Centers for Disease Control and Prevention (CDC) recommends annual chlamydia testing for all sexually active women aged ≤25 years and for older women with risk factors (new or multiple partners) 1, 3
  • The CDC recommends annual gonorrhea testing for all sexually active women aged <25 years and older women at increased risk, and for men based on risk factors and in high-prevalence settings 1, 2
  • The CDC recommends HIV testing for all persons at risk of STDs (sexually active and not in a mutually monogamous relationship with an uninfected partner) 1, 3
  • The American Academy of Family Physicians recommends syphilis testing for individuals with high-risk sexual behavior and in communities with high prevalence 2, 4

Additional Tests Often Included

  • The CDC recommends hepatitis B surface antigen (HBsAg) testing, particularly for pregnant women and high-risk individuals 4, 5
  • The CDC recommends hepatitis C testing based on guidelines, particularly for high-risk populations 1, 3
  • The CDC recommends trichomoniasis testing for women, especially those with symptoms or high risk 6

Population-Specific Considerations

  • The American College of Obstetricians and Gynecologists recommends standard screening to include chlamydia and gonorrhea for sexually active women under 25 years 2
  • The CDC recommends trichomoniasis testing for women with symptoms or risk factors 6
  • The CDC recommends bacterial vaginosis testing for women with vaginal discharge or odor 7
  • The CDC recommends comprehensive testing, including rectal and pharyngeal sites for chlamydia and gonorrhea, for men who have sex with men (MSM) 3

Testing Frequency

  • The CDC recommends annual screening for most at-risk populations 1, 2
  • The CDC recommends more frequent testing (e.g., every 3-6 months) for individuals with ongoing high-risk behaviors 6, 8
  • The CDC recommends rescreening at 3 months after treatment for those diagnosed with chlamydia or gonorrhea 3